The present invention relates to a polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the bicyclic peptides of the invention are conjugated to a carrier peptide in order to greatly enhance the bacterial cell killing activity. More particularly, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs), such as PBP3 and PBP3a. The invention also includes pharmaceutical compositions comprising said conjugates and to the use of said conjugates in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.

The present invention provides specific peptide biomarkers and sets of peptide biomarkers for use in methods of detecting or identifying bacterial biomarkers in a sample, wherein said bacterial biomarkers can be used to detect Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and/or Moraxella catarrhalis in a sample. Kits and diagnostic methods are also provided.

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

The present invention relates to the use of the recombinant antibacterial protein Ablysin for effectively killing multidrug-resistant pathogenic bacteria. The recombinant protein Ablysin of the present invention exhibits apoptosis against antibiotic-resistant Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecium to prevent or treat infectious diseases caused by these bacteria and thus it can be widely used in antibiotics, disinfectants, food additives, feed additives, and the like. In particular, the Ablysin uses peptidoglycan, which is a component of the cell wall of bacteria, as a substrate, and exhibits bacterial killing ability due to peptidoglycan degradation. The peptidoglycan exists only in bacteria and not in humans or animals, and thus there is an advantage that Ablysin of the present invention is safe because it does not affect humans and animals, and can be applied to the pharmaceutical industry, food industry, biotechnology, etc., as well as can effectively kill bacteria in a target place or a target substance without problems of resistance to antimicrobial agents.

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

A composition, transgenic organism, and method of protecting against desiccation or heat are provided. The composition includes a DtpA protein or complement thereof and a heterologous biologic. The transgenic organism includes the nucleic acid sequence according to SEQ ID NO: 1. The method includes contacting a heterologous biologic or organism with a DtpA protein and/ or a complement thereof.

The present invention provides a peptide that disrupts the self-aggregation of an AtaA polypeptide or separates a bond between the AtaA polypeptide and another subject. A peptide found by the present inventors has the properties of disrupting the self-aggregation of an AtaA polypeptide or separating a bond between the AtaA polypeptide and another subject. A peptide according to the present disclosure includes amino acid sequences AVL, SVL, ATL, or functional equivalent sequences thereof. In one embodiment, a peptide according to the present disclosure has the ability to separate a bond between an AtaA and other molecules (for example, streptavidin and neutral avidin).

The present invention provides a novel polypeptide. The polypeptide found by the inventors of the present invention does not have self-cohesive properties and has adhesive properties. The adhesive polypeptide according to the present invention comprises a fragment of the amino acid sequence represented by SEQ ID NO: 1. The adhesive polypeptide according to a specific embodiment of the present invention includes, from among the amino acid sequence represented by SEQ ID NO: 1, amino acids at positions 22-50 and positions 161-175, and also includes, from among amino acids at positions 2847-3093, deletion of a region required to impart self-cohesive properties.

Immunogenic proteins from Moraxella catharrhalis as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Methods for prophylaxis of infection with Moraxella catharrhalis using the proteins, nucleic acids, vectors or transformed cells.

Provided herein are glycoproteins containing O-linked glycosylation recognition motifs, and methods of making, for example, for use in the production of conjugate vaccines.